secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0000950170-23-062903
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology Q3 net loss $51.0M; positive Phase 2 gastric cancer data; CEO change
--------------------------------------------------------------------------------

- Q3 2023 GAAP net loss $51.0M ($1.24/diluted share) vs $35.3M ($0.87) in Q3 2022.
- Cash, equivalents and investments $196.4M; runway into early 2026 including recent $63.2M offering proceeds.
- Interim Phase 2 ASPEN-06: confirmed ORR 52% for evorpacept combo arm vs 22% for control in HER2+ gastric/GEJ cancer.
- Leadership realignment: Jason Lettmann appointed CEO, Jaume Pons becomes President and CSO.
- Closed public offering of common stock and pre-funded warrants in Oct 2023 for gross proceeds ~$63.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017023062903/0000950170-23-062903-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017023062903/alxo-20231113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062903

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer